43P - Health care utilization and burden of lung cancer over the last decade: A nationwide analysis

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Bioethics, Legal, and Economic Issues
Lung and other Thoracic Tumours
Presenter Supreet Kaur
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors S. Kaur1, D. Mehta2, A. Kumar3, M. Kumar3, M. Maroules3
  • 1Internal Medicine, St. Joseph's Regional Medical Center, 07503 - Paterson/US
  • 2Internal Medicine, New York Medical College, 10595 - Valhalla/US
  • 3Hematology-oncology, St. Joseph's Regional Medical Center, 07503 - Paterson/US

Abstract

Background

Lung cancer is the second most common malignancy and a leading cause of hospitalization and death in United States. Over the past two decades, our ability to treat lung cancer and associated complications has significantly improved. We aim to determine the incidence and costs of hospital admission associated with lung cancer using a nationally representative database.

Methods

We reviewed the National Inpatient Sample Database (NIS) for all hospitalizations in which lung cancer (ICD9 code 162.3, 162.4 and 162.5) was the principal discharge diagnosis during the period from 2000–2011 and calculated the population incidence using US Census data. We then analyzed changes in temporal trends of incidence, length of stay, costs and in-hospital mortality utilizing Cochrane-Armitage test.

Results

There were 978,254 primary admissions for lung cancer during the study period. In-hospital mortality for the cohort was up to 6.45% (n = 63136). The population incidence (lung cancer admissions/million people) decreased significantly from 1435 cases/million in 2000 to 1188 cases/million in 2011 (P 

Conclusions

The population incidence for inpatient lung cancer hospitalizations in the USA is decreasing. Reasons for this decrease could be in part related to increased use of diagnostic imaging leading to increased outpatient diagnosis. Other reasons need to be explored in detail. However, reassuringly the inpatient mortality is significantly decreased indicating better in-hospital care, improved chemotherapy regimens, targeted therapies and palliative care. This is consistent with CDC data on mortality in lung cancer. Despite decrease in the length of stay, the costs of hospitalizations have increased substantially, providing a niche for value based care intervention in this vulnerable population.

Clinical trial identification

Legal entity responsible for the study

hcupnet-cdc St Joseph Regional medical Center

Funding

N/A (Data available in public domain for research purposes)

Disclosure

All authors have declared no conflicts of interest.